focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK investigator says Chinese officials mistreated him to get GSK confession

Thu, 18th Jun 2015 10:30

LONDON/BEIJING, June 18 (Reuters) - A British corporateinvestigator freed from a Chinese jail last week has accusedofficials there of deliberately withholding medical treatment totry to force him to confess to a role in a scandal involvingdrugmaker GlaxoSmithKline Plc (GSK).

Peter Humphrey and his American wife Yu Yingzeng returned toBritain on Wednesday evening after being sentenced in August forillegally obtaining private records of Chinese citizens andselling the information to clients, including GSK.

Their case unfolded alongside a Chinese investigation of GSKthat led to a $489 million fine and has been held up as anexample of the potential risks faced by foreigners gatheringinformation in China.

"We arrive here with a heavy toll on our health," Humphreysaid in comments emailed to Reuters via a family friend. "I havea prostate tumour and Ying has kidney disease.

Humphrey, who has disputed allegations of wrongdoing, saidduring his time in jail, prison officers deliberately obstructedhis requests for the appropriate medical attention.

"Every week in captivity I raised requests for the next stepin the medical process," he said. "I was always refused on thegrounds that I had not signed an admission of crime.

"Neither I nor Ying have ever admitted any guilt as charged.We were not guilty of the offence with which we were charged andconvicted but my health was held hostage to signing such aconfession."

Chinese Foreign Ministry spokesman Lu Kang said thatHumphrey's allegations about mistreatment were "not true".

"The relevant Chinese authorities acted in accordance withthe law and guaranteed his rights," Lu told reporters at a dailynews briefing.

Asked about Humphrey's claims of a forced confession, Lusaid, "I am astonished about this. It seems that his stance wasdifferent before and after."

Humphrey and Yu, who ran risk consultancy ChinaWhys, hadbeen asked by GSK to compile a report into the origins of a sexvideo involving the drug company's former China head, MarkReilly, which had been sent to senior executives at GSK alongwith anonymous emails alleging corruption.

At the time, a GSK spokesman confirmed the video existed butdid not comment on how it related to the alleged briberyscandal. He also said GSK, Britain's largest pharmaceuticalfirm, had hired ChinaWhys to investigate the video. (Reporting by Kate Holton in London and Ben Blanchard and JohnRuwitch in Beijing; Editing by Louise Ireland and Andrew Osborn)

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.